Relievant Medsystems announced today that it released its Intracept simulator system, a training platform for the Intracept procedure. Further progress for Relievant and Intracept follows Tuesday’s major news of an agreement for Boston Scientific to acquire the company. Boston Scientific officials went into further detail on their expectations for the Relievant deal at the company’s […]
Pain Management
Boston Scientific targets M&A, AI to reach ‘next level’
Mike Mahoney uses fantasy football to describe Boston Scientific : He says that, if creating a medtech team, “it would be the draft you want.” Speaking at the company’s 2023 Investor Day event, the CEO set the theme as “next level.” He explained his aim to make Boston Scientific a “compelling” and “fantastic place to […]
Boston Scientific to acquire nerve ablation tech developer Relievant Medsystems for $850M
Boston Scientific announced today that it entered into a definitive agreement to acquire Relievant Medsystems. The transaction includes an upfront cash payment of $850 million. Additional payments are contingent on sales performance over the next three years. Minneapolis-based Relievant developed and commercialized the Intracept intraosseous nerve ablation system for chronic pain. The minimally invasive, FDA-cleared, […]
Medtronic wins CE mark for Inceptiv spinal cord stimulation system
Medtronic announced today that it received CE mark approval for its Inceptiv spinal cord stimulator (SCS). Inceptiv, a closed-loop, rechargeable SCS, treats chronic pain. Medtronic said it’s the company’s first SCS device to offer a closed-loop feature. This feature senses each person’s unique biological signals, adjusting stimulation moment-to-moment as needed. Medtronic says that keeps therapy […]
2-year data shows painful diabetic neuropathy relief with Nevro spinal cord stimulation
Nevro (NYSE:NVRO) today announced 24-month data from its Senza painful diabetic neuropathy (PDN) spinal cord stimulation (SCS) trial. Redwood City, California-based Nevro published its study results in Diabetes Research and Clinical Practice. The trial evaluated the long-term efficacy of high-frequency 10 kHz SCS to treat refractory PDN. It compared patients receiving the Senza HFX SCS […]
Nevro stock is down on slashed 2023 guidance
Nevro (NYSE: NVRO) stock lost more than a fifth of its value this morning — a day after the maker of spinal cord stimulation devices greatly reduced its full-year guidance. Redwood City, California–based Nevro now expects full-year 2023 revenue of roughly $410–415 million, an increase of 1–2% over 2022. The previous guidance was for $445–455 […]
Tivic Health reduces workforce as it may face Nasdaq delisting
Tivic Health (Nasdaq:TIVC) CEO Jennifer Ernst issued a letter to investors updating them on the current situation at the bioelectronic medicine developer. Ernst’s letter included the announcement that the company took several measures to fortify its position. That includes a reduction in force and internal restructuring. The company did not disclose further details about the […]
U.S. military to test Bexson Biomedical ketamine delivery device
Bexson Biomedical announced that the U.S. military intends to field-test its Akeso wearable ketamine delivery device. Akeso, a ruggedized version of Bexson Biomedical’s wearable infusion device, utilizes Sevalent technology. Sevalent, Bexson’s proprietary formulation platform can work with small molecules across a broad range of drug classes. It enables subcutaneous intravenous (IV) therapy delivery. Bexson management […]
NeuroMetrix is expanding its salesforce
NeuroMetrix (Nasdaq: NURO) second-quarter results took a hit from challenges related to reimbursement changes at CMS, but Quell Fibromyalgia saw positive trends. The Woburn, Massachusetts–based company’s Quell neuromodulation device won FDA de novo nod to treat fibromyalgia in May 2022. The company had 123 unique prescribers for the fibromyalgia therapy in Q2, versus 92 in […]
NeuroOne prices $5.25M public offering
NeuroOne Medical Technologies (Nasdaq:NMTC) announced today that it priced an underwritten registered public offering. Eden Prairie, Minnesota-based NeuroOne’s offering includes 5.25 million shares of common stock priced at $1 per share. All shares included in the offering will be sold by the company. NeuroOne also granted the underwriter a 30-day option to purchase up to […]
4-year data backs Relievant Medsystems’ Intracept ablation procedure
Relievant Medsystems announced four-year pooled data from two prospective clinical trials that support the use of its Intracept procedure. Intracept — a minimally invasive, FDA-cleared, same-day, outpatient procedure — treats chronic vertebrogenic low back pain. The procedure utilizes targeted radiofrequency energy to ablate the basivertebral nerve (BVN). This stops the nerve from transmitting pain signals […]
